E. Jermann

Radiometal-Labelled Macrocyclic Chelator-Derivatised Somatostatin Analogue with Superb Tumour-Targeting Properties and Potential for Receptor-Mediated Internal Radiotherapy

A. Heppeler, Sylvie Froidevaux, Helmut R. Mäcke et al. · Chemistry - A European Journal · 1999 · 334 citations · Full text

Medicine, Medicinal Chemistry, Nuclear Medicine +17

DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy

Andreas Otte, E. Jermann, Martin Béhé et al. · European Journal of Nuclear Medicine and Molecular Imaging · 1997 · 214 citations

Medicine, Molecular Pharmaceutics, Nuclear Medicine +14

Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy

Marion de Jong, Willem H. Bakker, Eric P. Krenning et al. · European Journal of Nuclear Medicine and Molecular Imaging · 1997 · 212 citations

Medicine, Nuclear Medicine, Pharmacology +17

Biokinetics and dosimetry in patients administered with 111 In-DOTA-Tyr 3 -octreotide: implications for internal radiotherapy with 90 Y-DOTATOC

Marta Cremonesi, Mahila Ferrari, Stefania Zoboli et al. · European Journal of Nuclear Medicine and Molecular Imaging · 1999 · 151 citations

Medicine, Nuclear Medicine, Pharmacokinetics +14

Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas.

Adrian Merlo, Oliver Hausmann, M. Wasner et al. · PubMed · 1999 · 96 citations

Medicine, Oncology, Pharmacology +17